Mixed connective tissue disease--goodbye to all that.
Since it was first described mixed connective tissue disease (MCTD) has been the subject of much debate. In particular the question of whether it is a truly distinctive disease entity has been challenged. It seems clear that the original description of MCTD as a mild disorder, rarely affecting the lungs or kidneys and requiring small doses of corticosteroids only, is no longer tenable. In this review a historical analysis of the clinical and serological features is presented. It is suggested that the concept of MCTD as a distinct disease entity is better replaced by the term 'undifferentiated autoimmune rheumatic/connective tissue disorder'. Many of these patients will later 'convert' into scleroderma or lupus; some will remain undifferentiated.
Black
C
C
Department of Rheumatology, Royal Free Hospital, London.
Isenberg
D A
DA
D001323:Autoantibodies / Q000378:metabolism; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000473:pathology; D008947:Mixed Connective Tissue Disease / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D015995:Prevalence; D011379:Prognosis; D017412:Ribonucleoprotein, U1 Small Nuclear / Q000276:immunology; D012595:Scleroderma, Systemic / Q000473:pathology
D001323:Autoantibodies; D001324:Autoantigens; D017412:Ribonucleoprotein, U1 Small Nuclear